Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study.

Lampe FC, Porter K, Kaldor J, Law M, Kinloch-de Loes S, Phillips AN; CASCADE Collaboration.

Antivir Ther. 2007;12(2):189-93.

PMID:
17503661
2.

Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.

Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, de Lazzari E, Dauer B, Youle M, Fontas E, Krentz HB, Phillips AN.

Arch Intern Med. 2006 Mar 13;166(5):521-8.

PMID:
16534038
3.

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, Garcia F, Ellefsen K, Podzamczer D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, Hardy WD, Mitsuyasu R, Moyle G, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B, Baksaas I, Jolliffe D, Persson S, Jelmert O, Hovden AO, Sommerfelt MA, Wendel-Hansen V, Sørensen B.

Lancet Infect Dis. 2014 Apr;14(4):291-300. doi: 10.1016/S1473-3099(13)70343-8. Epub 2014 Feb 11.

4.

Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database.

Zhou J, Sirisanthana T, Kiertiburanakul S, Chen YM, Han N, Lim PL, Kumarasamy N, Choi JY, Merati TP, Yunihastuti E, Oka S, Kamarulzaman A, Phanuphak P, Lee CK, Li PC, Pujari S, Saphonn V, Law MG.

BMC Infect Dis. 2010 Dec 23;10:361. doi: 10.1186/1471-2334-10-361.

5.

The effect of antiretroviral treatment of different durations in primary HIV infection.

Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC, Porter K; CASCADE Collaboration.

AIDS. 2008 Nov 30;22(18):2441-50. doi: 10.1097/QAD.0b013e328319ea4e.

PMID:
19005267
6.

Changes in HIV RNA and CD4 cell count after acute HCV infection in chronically HIV-infected individuals.

Gras L, de Wolf F, Smit C, Prins M, van der Meer JT, Vanhommerig JW, Zwinderman AH, Schinkel J, Geskus RB; ATHENA national observational cohort and the MOSAIC study.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):536-42. doi: 10.1097/QAI.0000000000000514.

PMID:
25559595
7.

Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD).

Oyomopito R, Lee MP, Phanuphak P, Lim PL, Ditangco R, Zhou J, Sirisanthana T, Chen YM, Pujari S, Kumarasamy N, Sungkanuparph S, Lee CK, Kamarulzaman A, Oka S, Zhang FJ, Mean CV, Merati T, Tau G, Smith J, Li PC; TREAT Asia HIV Observational Database.

HIV Med. 2010 Sep;11(8):519-29. doi: 10.1111/j.1468-1293.2010.00822.x. Epub 2010 Mar 21.

8.

A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.

Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S; AIEDRP Network.

J Infect Dis. 2006 Sep 15;194(6):725-33. Epub 2006 Aug 15.

PMID:
16941337
9.

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.

Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, Losso M, Lazzarin A, Fatkenheuer G, Lundgren JD; EuroSIDA study group.

Lancet. 2007 Aug 4;370(9585):407-13.

PMID:
17659333
10.

Short-course antiretroviral therapy in primary HIV infection.

SPARTAC Trial Investigators, Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A.

N Engl J Med. 2013 Jan 17;368(3):207-17. doi: 10.1056/NEJMoa1110039.

11.

The effect of opportunistic illness on HIV RNA viral load and CD4+ T cell count among HIV-positive adults taking antiretroviral therapy.

Ekwaru JP, Campbell J, Malamba S, Moore DM, Were W, Mermin J.

J Int AIDS Soc. 2013 Apr 1;16:17355. doi: 10.7448/IAS.16.1.17355.

12.

Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.

Wyl Vv, Gianella S, Fischer M, Niederoest B, Kuster H, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B, Günthard HF; Swiss HIV Cohort Study-SHCS.

PLoS One. 2011;6(11):e27463. doi: 10.1371/journal.pone.0027463. Epub 2011 Nov 15.

13.

Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.

Cochrane Database Syst Rev. 2014 May 22;(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. Review.

PMID:
24852077
14.

Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.

Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, Sannes M, Porter K.

Arch Intern Med. 2012 Sep 10;172(16):1252-5. doi: 10.1001/archinternmed.2012.2719.

PMID:
22826124
15.

Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.

Lapadula G, Cozzi-Lepri A, Marchetti G, Antinori A, Chiodera A, Nicastri E, Parruti G, Galli M, Gori A, Monforte Ad; ICONA Foundation Study.

AIDS. 2013 Mar 13;27(5):769-79. doi: 10.1097/QAD.0b013e32835cb747.

PMID:
23719349
16.

Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.

Pai NP, Lawrence J, Reingold AL, Tulsky JP.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD006148. Review.

PMID:
16856117
17.

HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.

Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix ML, Jacomet C, Talamali A, Delfraissy JF, Venet A, Meyer L, Sinet M; ANRS CO6 PRIMO Study Group.

Antivir Ther. 2012;17(6):1001-9. doi: 10.3851/IMP2273. Epub 2012 Aug 6.

PMID:
22865544
18.

CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.

Wolbers M, Battegay M, Hirschel B, Furrer H, Cavassini M, Hasse B, Vernazza PL, Bernasconi E, Kaufmann G, Bucher HC; Swiss HIV Cohort Study.

Antivir Ther. 2007;12(6):889-97.

PMID:
17926643
19.

Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries.

Raboud JM, Loutfy MR, Su D, Bayoumi AM, Klein MB, Cooper C, Machouf N, Rourke S, Walmsley S, Rachlis A, Harrigan PR, Smieja M, Tsoukas C, Montaner JS, Hogg RS; CANOC Collaboration.

BMC Infect Dis. 2010 Feb 25;10:40. doi: 10.1186/1471-2334-10-40.

20.

Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.

Hocqueloux L, Avettand-Fènoël V, Jacquot S, Prazuck T, Legac E, Mélard A, Niang M, Mille C, Le Moal G, Viard JP, Rouzioux C; AC32 (Coordinated Action on HIV Reservoirs) of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS).

J Antimicrob Chemother. 2013 May;68(5):1169-78. doi: 10.1093/jac/dks533. Epub 2013 Jan 20.

PMID:
23335199

Supplemental Content

Support Center